mbi-226 and Candidiasis

mbi-226 has been researched along with Candidiasis* in 2 studies

Other Studies

2 other study(ies) available for mbi-226 and Candidiasis

Article	Year
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:3 Omiganan, a bactericidal and fungicidal cationic peptide being developed as a topical gel for prevention of catheter-associated infections, inhibited commonly occurring fungal pathogens including Candida spp. (106 isolates) at Topics: Antifungal Agents; Antimicrobial Cationic Peptides; Aspergillosis; Aspergillus; Candida; Candidiasis; Catheterization, Central Venous; Dose-Response Relationship, Drug; Drug Resistance, Fungal; Fungemia; Fungi; Humans; Microbial Sensitivity Tests	2008
Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity. Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:8 The activity of omiganan pentahydrochloride (formerly MBI 226; a synthetic cationic peptide) was assessed against 1,437 recent clinical bacterial isolates and 214 recent clinical yeast isolates. The omiganan was highly active, and minimal bactericidal concentrations or minimal fungicidal concentrations were either equal to or two- to fourfold higher than MICs. Kill curve experiments showed a clear pattern of bactericidal activity. Topics: Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Bacteria; Bacterial Infections; Candida; Candidiasis; Colony Count, Microbial; Drug Stability; Freezing; Humans; Kinetics; Microbial Sensitivity Tests; Oxacillin; Penicillin Resistance; Penicillins; Vancomycin Resistance	2004

Article

Year

Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.

Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:3

Omiganan, a bactericidal and fungicidal cationic peptide being developed as a topical gel for prevention of catheter-associated infections, inhibited commonly occurring fungal pathogens including Candida spp. (106 isolates) at

Topics: Antifungal Agents; Antimicrobial Cationic Peptides; Aspergillosis; Aspergillus; Candida; Candidiasis; Catheterization, Central Venous; Dose-Response Relationship, Drug; Drug Resistance, Fungal; Fungemia; Fungi; Humans; Microbial Sensitivity Tests

2008

Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity.

Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:8

The activity of omiganan pentahydrochloride (formerly MBI 226; a synthetic cationic peptide) was assessed against 1,437 recent clinical bacterial isolates and 214 recent clinical yeast isolates. The omiganan was highly active, and minimal bactericidal concentrations or minimal fungicidal concentrations were either equal to or two- to fourfold higher than MICs. Kill curve experiments showed a clear pattern of bactericidal activity.

Topics: Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Bacteria; Bacterial Infections; Candida; Candidiasis; Colony Count, Microbial; Drug Stability; Freezing; Humans; Kinetics; Microbial Sensitivity Tests; Oxacillin; Penicillin Resistance; Penicillins; Vancomycin Resistance

2004